Literature DB >> 6810755

Comparative in vitro activities of beta-lactam-tobramycin combinations against Pseudomonas aeruginosa and multidrug-resistant gram-negative enteric bacilli.

R J Fass.   

Abstract

Piperacillin was more consistently active than tobramycin, carbenicillin, moxalactam, or ceftriaxone against strains of Pseudomonas aeruginosa isolated from blood cultures and against multidrug-resistant strains. Moxalactam and ceftriaxone were more consistently active than tobramycin, carbenicillin, or piperacillin against multidrug-resistant Enterobacteriaceae. Synergy between beta-lactam antibiotics and tobramycin was frequently observed against strains of P. aeruginosa isolated from blood cultures but not against multidrug-resistant organisms. Piperacillin plus tobramycin was the most active antibiotic combination against P. aeruginosa. Moxalactam plus tobramycin and ceftriaxone plus tobramycin were the most active antibiotic combinations against Enterobacteriaceae.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6810755      PMCID: PMC182062          DOI: 10.1128/AAC.21.6.1003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Analysis of the interactions between piperacillin, ticarcillin, or carbenicillin and aminoglycoside antibiotics.

Authors:  P Chanbusarakum; P R Murray
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

2.  Antimicrobial activity of tobramycin and gentamicin used in combination with cephalothin and carbenicillin.

Authors:  J Klastersky; A Henri; L Vandenborre
Journal:  Am J Med Sci       Date:  1973-07       Impact factor: 2.378

3.  Susceptibility of gram-negative aerobic bacilli resistant to carbenicillin in a general hospital to piperacillin and ticarcillin.

Authors:  J E McGowan; P M Terry
Journal:  Antimicrob Agents Chemother       Date:  1979-01       Impact factor: 5.191

4.  Piperacillin, a new penicillin active against many bacteria resistant to other penicillins.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

5.  Susceptibility of cephalothin-resistant gram-negative bacilli to piperacillin, cefuroxime, and other selected antibiotics.

Authors:  W L George; R P Lewis; R D Meyer
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

6.  Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin.

Authors:  H C Neu; N J Meropol; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

7.  Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa.

Authors:  L Mintz; W L Drew
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

8.  Comparative in vitro synergistic activity of new beta-lactam antimicrobial agents and amikacin against Pseudomonas aeruginosa and Serratia marcescens.

Authors:  T O Kurtz; D J Winston; D A Bruckner; W J Martin
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

9.  In vitro activities of beta-lactam and aminoglycoside antibiotics. A comparative study of 20 parenterally administered drugs.

Authors:  R J Fass
Journal:  Arch Intern Med       Date:  1980-06

10.  In vitro activity of LY127935.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1979-10       Impact factor: 5.191

View more
  15 in total

1.  Comparison of the serum bactericidal activity of ceftriaxone/piperacillin and ceftriaxone/netilmicin.

Authors:  K Machka; M Röbl; I Braveny
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

Review 2.  Antibiotic combinations: should they be tested?

Authors:  G M Eliopoulos; C T Eliopoulos
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

3.  Synergistic activity of aminoglycoside-beta-lactam combinations against Pseudomonas aeruginosa with an unusual aminoglycoside antibiogram.

Authors:  R B Clark; C B Pakiz; M K Hostetter
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

4.  Comparative synergistic activity of ceftriaxone-piperacillin versus ceftriaxone-netilmicin.

Authors:  K Machka; R Dietz
Journal:  Eur J Clin Microbiol       Date:  1983-10       Impact factor: 3.267

5.  Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.

Authors:  Rajbharan Yadav; Kate E Rogers; Phillip J Bergen; Jürgen B Bulitta; Carl M J Kirkpatrick; Steven C Wallis; David L Paterson; Roger L Nation; Jeffrey Lipman; Jason A Roberts; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

Review 6.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 7.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

8.  Synergistic activities of combinations of beta-lactams, fosfomycin, and tobramycin against Pseudomonas aeruginosa.

Authors:  K Takahashi; H Kanno
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

9.  Synergy of ciprofloxacin and azlocillin in vitro and in a neutropenic mouse model of infection.

Authors:  N X Chin; K Jules; H C Neu
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

10.  In vitro activity of ceftriaxone alone and in combination with gentamicin, tobramycin, and amikacin against Pseudomonas aeruginosa.

Authors:  C Watanakunakorn
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.